Xu Y - Search Results

1

Predicting bleeding risk in a Chinese immune thrombocytopenia (ITP) population: development and assessment of a new predictive nomogram.

Wang M, Liu W, Xu Y, Wang H, Guo X, Ding X, Quan R, Chen H, Zhu S, Fan T, Li Y, Zhang X, Sun Y, Hu X. Wang M, et al. Among authors: xu y. Sci Rep. 2020 Sep 18;10(1):15337. doi: 10.1038/s41598-020-72275-1. Sci Rep. 2020. PMID: 32948823 Free PMC article.

2

[Immunophenotypic features in leukemia of NK cell series].

Ma R, Xu YG, Yang XH, Hu XM, Li L, Tang XD, Zhang SS, Xu S, Wang HZ, Liu F. Ma R, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Feb;14(1):35-8. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006. PMID: 16584587 Chinese.

3

[Effect of treatment for myelodysplastic syndrome by Qinghuang Powder combined with Chinese herbs for reinforcing shen and strenghening pi].

Xu S, Hu XM, Xu YG. Xu S, et al. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008 Mar;28(3):216-8. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008. PMID: 18476419 Chinese.

4

Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy.

Hu XM, Liu F, Zheng CM, Li L, Liu C, Zhang SS, Xiao HY, Yang XH, Wang HZ, Xu YG, Hu NP, Ma R. Hu XM, et al. Chin J Integr Med. 2009 Jun;15(3):193-7. doi: 10.1007/s11655-009-0193-x. Epub 2009 Jul 2. Chin J Integr Med. 2009. PMID: 19568712 Clinical Trial.

5

Clinical observation of the treatment of myelodysplastic syndrome mainly with Qinghuang Powder.

Xu S, Ma R, Hu XM, Xu YG, Yang XH, Wang HZ, Sun SZ, Liu F. Xu S, et al. Chin J Integr Med. 2011 Nov;17(11):834-9. doi: 10.1007/s11655-011-0894-9. Epub 2011 Nov 6. Chin J Integr Med. 2011. PMID: 22057412 Clinical Trial.

6

Effect of Qinghuang Powder () Combined with Bupi Yishen Decoction () in Treating Patients with Refractory Cytopenia with Multilineage Dysplasia through Regulating DNA Methylation.

Zhou QB, Yang XH, Wang HZ, Wang DX, Xu YG, Hu XM, Xu FQ, Ma R. Zhou QB, et al. Chin J Integr Med. 2019 May;25(5):354-359. doi: 10.1007/s11655-018-2554-9. Epub 2018 Mar 2. Chin J Integr Med. 2019. PMID: 29500545 Clinical Trial.

7

[Secretory Imbalance between Pro-inflammatory and Anti-inflammatory Cytokines in the Patients with Immune Thrombocytopenia].

Wang MJ, Xu YG, Ding XQ, Quan RC, Chen HY, Deng ZY, Zhao P, Fan T, Zhu SR, Hu XM. Wang MJ, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018 Apr;26(2):522-527. doi: 10.7534/j.issn.1009-2137.2018.02.036. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018. PMID: 29665926 Chinese.

8

[Level of Regulatory B Cells in Patients with Immune Thrombocytopenia and Its Clinical Significance].

Zhu SR, Chen HY, Wang MJ, Xu YG, Quan RC, Ding XQ, Zhao P, Wang HZ, Guo XQ, Hu XM. Zhu SR, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Feb;27(1):175-179. doi: 10.7534/j.issn.1009-2137.2019.01.028. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019. PMID: 30738466 Chinese.

9

Relation of Blood Arsenic Concentration with Effect and Safety of Arsenic-Containing Qinghuang Powder () in Patients with Myelodysplastic Syndrome.

Deng ZY, Zhu SR, Wang MJ, Fang S, Zhao P, Zhu QZ, Wang HZ, Guo XQ, Xu YG, Yi BW, Shang XH, Ma R, Hu XM. Deng ZY, et al. Chin J Integr Med. 2019 Jul;25(7):497-501. doi: 10.1007/s11655-019-3070-2. Epub 2019 Jul 5. Chin J Integr Med. 2019. PMID: 31278627 Clinical Trial.

10

Arsenic-Containing Qinghuang Powder () is an Alternative Treatment for Elderly Acute Myeloid Leukemia Patients Refusing Low-Intensity Chemotherapy.

Fan T, Quan RC, Liu WY, Xiao HY, Tang XD, Liu C, Li L, Lv Y, Wang HZ, Xu YG, Guo XQ, Hu XM. Fan T, et al. Among authors: xu yg. Chin J Integr Med. 2020 May;26(5):339-344. doi: 10.1007/s11655-019-3050-6. Epub 2019 Dec 17. Chin J Integr Med. 2020. PMID: 31848890

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

73,455 results

Search Page

Filters